Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Healthcare Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Sernova Corp > Presentation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by MustangSalleyon Apr 08, 2021 11:26pm
121 Views
Post# 32964684

RE:RE:RE:RE:RE:RE:Presentation

RE:RE:RE:RE:RE:RE:Presentation
Redbaron2211 wrote:
Sailboatdream wrote:

to my knowledge, AGM's are mandatory in Canada for public companies.  Also, I would disagree that "waiting game", lack of information, lack of progress on commitments (I.e. completing diabetes trials cohort in Q1) and inability to properly capitalize on the amazing results published in Jan is a valid investment strategy.  
 



Metals you call this common sense??  No understanding on NDAs while failing to see how there would be no AGM after a company is bought out?

Those "80mil shares"  will be happy pretty quick if a licensing deal materializes.  Boils down to impatient investors.


 

Red, 

I would happy with a licensing deal or deal with pharma with cash in .But I am more realistic than you.   Tolekis does not have the skill set or help to pull off a licending deal.  He does collaborations in the past with pharma and has got nothing back.  The excuse : new management is going in a different direction ... how many times in the past ten years ? 


How about Sernova's management go in a different direction ? I bet Tolekis promises a licensing deal AFTER the AGM...  just a hunch .

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities